The global Biliary Atresia Treatment Market is estimated to be valued at US$ 1,064.2 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2027 to 2030, as highlighted in a new report published by Coherent Market Insights.
Biliary Atresia is a rare chronic disease affecting bile ducts of infants. The treatment involves surgical procedures and medications to repair damaged bile ducts or replace organ functions. Treatment options include portoenterostomy surgery, liver transplant, and medications.
Market Overview:
The biliary atresia treatment market comprises products used for surgical procedures and medication therapies to treat biliary atresia in infants and children. Key treatment products include antibiotics, steroids, ursodeoxycholic acid, and transplant medications. Growing prevalence of biliary atresia and new drug approvals are boosting the market growth.
Market key trends:
One of the key trends in the biliary atresia treatment market is increasing research on gene therapy and stem cell therapy. Researchers are exploring the possibility of correcting the genetic abnormalities causing biliary atresia using gene therapy techniques. Some studies show stem cell therapy may help regenerate damaged bile ducts and improve liver function in children with biliary atresia. Introduction of such novel treatment options can potentially change the treatment landscape in the coming years.
Market key trends:
One of the key trends in the Biliary Atresia Treatment Market is the increasing research and development activities for developing novel drugs and treatment options. Currently, surgery known as Kasai procedure is the only treatment available which involves bypassing the blocked bile ducts outside the liver. However, the success rate of this procedure decreases with age. This has led to higher investments by market players to come up with improved treatment alternatives. For instance, companies are exploring gene therapy and stem cell therapy to repair damaged bile ducts and treat the underlying cause.
SWOT Analysis
Strength: Growing research funding and government support for developing novel therapies presents an opportunity.
Weakness: Low success rate of existing Kasai procedure leaves a large unmet need.
Opportunity: Emerging alternative treatment options like drugs, gene therapy and stem cell therapy offer potential for better outcomes.
Threats: High costs associated with novel therapies development can affect market growth. Stringent regulations for approval also act as a challenge.
Key Takeaways
The global Biliary Atresia Treatment Market is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing research funding for developing advanced treatment options.
Regionally, North America is projected to dominate the global market due to presence of major market players and availability of advanced healthcare facilities for rare disease treatment. However, Asia Pacific region is likely to exhibit the highest growth rate owing to rising healthcare spending and increasing patient base.
Key players operating in the Biliary Atresia Treatment are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals. Major companies are focused on conducting trials for novel drug candidates and therapies in order to expand their product portfolios.
